Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
JTO CLINICAL AND RESEARCH REPORTS（2025）
Key words
Dual EGFR inhibition,Phase I trial,Lung cancer,EGFR-mutated
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined